Marrone Bio Innovations, Inc. (NASDAQ:MBII) received a $4.00 price target from analysts at HC Wainwright in a research report issued on Tuesday. The firm currently has a “buy” rating on the basic materials company’s stock. HC Wainwright’s price target suggests a potential upside of 288.35% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $2.50 price target on shares of Marrone Bio Innovations in a research report on Tuesday, May 2nd. ValuEngine upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Piper Jaffray Companies set a $1.00 price target on shares of Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. Finally, Zacks Investment Research upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Marrone Bio Innovations currently has a consensus rating of “Hold” and a consensus target price of $2.50.

Shares of Marrone Bio Innovations (MBII) traded down 6.36% on Tuesday, reaching $1.03. The company’s stock had a trading volume of 146,628 shares. The company’s market cap is $32.29 million. Marrone Bio Innovations has a 52-week low of $0.87 and a 52-week high of $2.79. The company has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.57.

Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Monday, August 14th. The basic materials company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $6.48 million during the quarter, compared to the consensus estimate of $6.62 million. On average, analysts anticipate that Marrone Bio Innovations will post ($0.92) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/15/marrone-bio-innovations-inc-mbii-given-a-4-00-price-target-at-hc-wainwright.html.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.